2025 annual financial data
4D Molecular Therapeutics 2025 Operating margin
Direct answer
Operating margin was -187.24%.
Operating income was -159,547,000 USD and net income was -140,109,000 USD.
Operating cash flow was -109,082,000 USD.
Get free 4D Molecular Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 85,209,000 USD
- Operating income
- -159,547,000 USD
- Net income
- -140,109,000 USD
- Operating cash flow
- -109,082,000 USD